Results 201 to 210 of about 1,207,383 (287)

Prognostic Factors for Patients Under 45 Undergoing Surgery for Colorectal Liver Metastases: A SEER Population-Based Study. [PDF]

J Surg Oncol
Grob G, Fang F, Karpov M, Feliberti E, Hughes M, Burke R, Lo W.   +6 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores. [PDF]

Updates Surg
Ammirabile A, Matteucci G, Fiz F, Ragaini E, Moroni S, Lanza E, Cavinato L, Galvanin J, Masci C, Costa G, Laghi A, Torzilli G, Ieva F, Viganò L.   +13 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases. [PDF]

Cancers (Basel)
Kataoka K, Kimura K, Imada A, Ito K, Rao Z, Fukumoto Y, Song J, Horio Y, Kuwahara R, Uchino M, Yoshino T, Oki E, Kanemitsu Y, Ikeda M.   +13 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Artificial intelligence-driven body composition analysis and its association with survival in patients with colorectal liver metastases. [PDF]

Contemp Oncol (Pozn)
Rozynek M, Tabor Z, Kłęk S, Popiela T, Wojciechowski W.   +4 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Oncologic Outcomes After Liver Transplantation for Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of Proportions. [PDF]

J Surg Oncol
Pompeu BF, Aguiar LR, Melillo GD, Nakabayashi LS, Barone GL, Delgado LM, Theis C, Grande LMD, Poli de Figueiredo SM, Formiga FB, Bressan AK.   +10 more
europepmc   +1 more source